TELMISIGN AM Tablet is a fixed-dose combination of two antihypertensive agents, Telmisartan and Amlodipine, formulated to provide dual-action control over blood pressure. Telmisartan belongs to the angiotensin II receptor blocker (ARB) class, while Amlodipine is a calcium channel blocker (CCB). Together, they work synergistically to lower elevated blood pressure more effectively than either agent alone.
Telmisartan helps by blocking the action of angiotensin II, a chemical that causes blood vessels to constrict. By inhibiting this action, it relaxes and widens blood vessels, allowing for smoother blood flow and reduced vascular resistance. Amlodipine works by relaxing the muscles of the heart and blood vessels, thereby reducing the workload on the heart and helping to prevent chest pain and arrhythmias associated with high blood pressure.
TELMISIGN AM is particularly beneficial for patients whose blood pressure is not adequately controlled with monotherapy. It is also useful in cases where combination therapy can help lower cardiovascular risk and improve adherence by simplifying treatment into a single daily dose. The once-daily dosing ensures 24-hour control of blood pressure and helps prevent fluctuations that can lead to cardiovascular events.
The combination is generally well-tolerated, though some patients may experience mild side effects such as dizziness, swelling of the ankles or feet, headache, or fatigue during the initiation of therapy. Serious adverse reactions are rare but may include hypotension, renal dysfunction, or allergic reactions. Regular monitoring of blood pressure, renal function, and electrolyte levels is recommended, especially during long-term use.
TELMISIGN AM should not be used during pregnancy or by individuals with known hypersensitivity to any of its components. Caution should be exercised in patients with liver or kidney disease. It is also advisable to consult a healthcare professional before starting therapy, especially for individuals on other medications for cardiovascular or renal conditions.
Manufactured under the strict quality control standards of Bluepill Express, TELMISIGN AM Tablet meets international regulatory and manufacturing norms, including WHO-GMP and ISO certifications. Each batch undergoes rigorous quality assurance tests, including stability analysis, dissolution profiling, impurity checks, and microbial load assessment. The product is packaged in moisture-resistant, tamper-proof strips to ensure optimal stability and shelf life.
Description provided by bluepill express.
FIEO Registered
Export Ready
